Search results for " Obstructive."

showing 7 items of 477 documents

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Stud…

2020

Roland Buhl,1 Michael Dreher,2 Stephanie Korn,1 Christian Taube,3 Christian Stock,4 Christoph M Zehendner,5 Anke Kondla,5 Claus F Vogelmeier6 1Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 2Clinic of Cardiology, Pneumology, Angiology and Internal Medicine Intensive Care, University Hospital RWTH Aachen, Aachen, Germany; 3Clinic for Pneumonology, University Medicine Essen – Ruhrlandklinik, Essen, Germany; 4Biostatistics + Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 5HP Country Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; 6Department of Pneumology,…

medicine.medical_specialtytiotropium/olodaterolMedizinMuscarinic AntagonistsInternational Journal of Chronic Obstructive Pulmonary Disease03 medical and health scienceschemistry.chemical_compoundStudy ProtocolPulmonary Disease Chronic Obstructive0302 clinical medicineMaintenance therapySpiolto® Respimat®Internal medicineAdministration Inhalationmedicinemedia_common.cataloged_instanceCOPDHumansMulticenter Studies as Topic030212 general & internal medicineProspective StudiesEuropean unionTiotropium BromideAdrenergic beta-2 Receptor Agonistsmedia_commonCOPDbiologybusiness.industryInhalerOlodaterolGeneral MedicineLamamedicine.diseasebiology.organism_classificationLAMA/LABA/ICShumanitiesObstructive lung diseaseBenzoxazinesBronchodilator AgentsRegimen030228 respiratory systemchemistrytriple therapyDrug Therapy Combinationbusinesshormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct

Association of child maltreatment subtypes and long-term physical health in a German representative sample

2018

ABSTRACT Background: Child maltreatment is a major public problem, associated with enormous consequences on the individual and socioeconomic level. Studies show a clear impact of child maltreatment on long-term physical health. However, there is a lack of analyses comprising a wide variety of subtypes of maltreatment and addressing cumulative effects of different maltreatment subtypes experienced during childhood on physical health. Objective: The objective of this analysis was to assess the association of different subtypes and the intensity of child maltreatment with long-term physical health outcomes. Methods: In a cross-sectional observational approach, a representative sample of the Ge…

obesityPsychological interventionObesidadChild abuse and neglectInfarto al Miocardio癌症心肌梗塞0302 clinical medicinelcsh:PsychiatryEnfermedad pulmonar obstructiva crónica030212 general & internal medicineStrokeClinical Research Articlediabetes05 social sciencesCáncerstrokemyocardial infarction• Studies addressing cumulative effects of different child maltreatment subtypes on physical health are sparse especially those comprising emotional and physical neglect.• Odds for obesity diabetes cancer hypertension chronic obstructive pulmonary disease history of myocardial infarction and stroke increased when any kind of child maltreatment was reported.• Growing intensity of each maltreatment subtype was associated with higher rates of all assessed conditions.• Odds for all conditions increased with increasing number of maltreatment subtypes that were experienced.Hipertensión Arterial050104 developmental & child psychologyClinical psychology虐待和忽视儿童medicine.medical_specialtyhypertension高血压lcsh:RC435-571中风physical health outcomesOddschronic obstructive pulmonary disease童年虐待肥胖糖尿病03 medical and health sciencesmedicinecancer0501 psychology and cognitive sciencesAbuso infantil y negligenciaSocioeconomic statusConsecuencias de Salud Físicabusiness.industryPublic healthCTQ treeApoplejíamedicine.diseaseObesity身体健康结果Maltrato infantil慢性阻塞性肺疾病Observational studybusinesschild maltreatmentEuropean Journal of Psychotraumatology
researchProduct

Sleep-disordered breathing in the elderly

2009

Purpose: The prevalence of sleep-disordered breathing (SDB) increases with aging. SDB is a risk of hypertension, and both might lead to cognitive decline. However, the role of SDB and hypertension on the pathogenesis of age-related cognitive decline remains unclear. We examined the effects of these two diseases on cognitive function in elderly adults.

obstructive sleep apnea central sleep apnea chronic heart failure chronic obstructive pulmonary diseaseSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Sleep Disturbances in COPD are Associated with Heterogeneity of Airway Obstruction

2018

Individuals with Chronic Obstructive Pulmonary Disease (COPD) experience sleep disturbances due to the impact of respiratory symptoms on sleep quality. We explored whether sleep disturbances in COPD are linked to heterogeneity of airway constriction.The impact of breathing problems on sleep quality was measured in consecutive COPD outpatients with the COPD and Asthma Sleep Impact Scale (CASIS) questionnaire. Impulse oscillometry technique (IOS) was employed to assess heterogeneity of airway constriction. Subjects with a previous or concomitant diagnosis of asthma or obstructive sleep apnea (OSA) were excluded.Fifty COPD subjects (M/F 40/10; age: 71 +/- 8 yrs, Body Mass Index (BMI): 26.2 +/-…

sleep abnormalitieMaleSleep Wake DisordersPulmonary and Respiratory Medicinemedicine.medical_specialtyPulmonary diseaseCASISSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeOscillometrySurveys and QuestionnairesInternal medicinemedicineCOPDHumansSleep Wake DisorderOximetry030212 general & internal medicineRespiratory systemOxyhemoglobinAgedIOSCOPDSleep qualitybusiness.industryMiddle AgedAirway obstructionmedicine.diseaseSleep in non-human animalsSleep abnormalitiesResidual Volume030228 respiratory systemOxyhemoglobinsCardiologyFemalebusinessHumanCOPD: Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Mode…

2020

Stefan Andreas,1,2 Lorcan McGarvey,3 Ulrich Bothner,4 Matthias Trampisch,4 Alberto de la Hoz,4 Matjaz Fležar,5 Roland Buhl,6 Peter Alter7 1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL); 3Queen’s University Belfast, Belfast, UK; 4Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 5Klinika Golnik, Golnik, Slovenia; 6Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; 7Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University of Marburg (UMR); Member o…

srčna frekvencamedicine.medical_specialtymedicine.drug_classDiastoleBlood PressureInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive -- drug therapychronic obstructive pulmonary disease03 medical and health scienceschemistry.chemical_compoundPulmonary Disease Chronic Obstructive0302 clinical medicinetiotropiumDouble-Blind MethodHeart RateInternal medicineBronchodilatorForced Expiratory VolumeHeart ratePost-hoc analysisheart ratemedicineHumans030212 general & internal medicineTiotropium BromideAdverse effectudc:616.2pulmonary diseasekrvni tlaktOriginal ResearchtiotropijCOPDbusiness.industryolodaterolkronična obstruktivna pljučna bolezen -- terapija z zdraviliOlodaterolblood pressureGeneral Medicinemedicine.diseasehumanities3. Good healthBenzoxazinesBronchodilator AgentsBlood pressureTreatment Outcome030228 respiratory systemchemistryCardiologybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct